 |
|
Estradiol in Breast Cancer TreatmentReviving the Past
Pamela N. Munster, MD;
John T. Carpenter, MD
JAMA. 2009;302(7):797-798.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Despite a declining incidence, breast cancer remains the most common cancer among women in the United States.1 More than two-thirds of all patients with breast cancer present with tumors that express estrogen receptors, progesterone receptors, or both, and the modulation of estrogen receptor signaling has been one of the most successful strategies for these patients. In recent years, the most commonly used forms of endocrine therapy have included the competitive inhibition of the estrogen receptors with an antiestrogen (selective estrogen receptor modulators [SERMs], eg, tamoxifen, or selective estrogen–receptor down-regulators, [SERDs], eg, fulvestrant) and the decrease in estrogen production from precursor steroid hormones using an aromatase inhibitor.
In this issue of JAMA, Ellis and colleagues2 describe the findings of a preliminary phase 2 randomized study, evaluating the efficacy of 2 daily doses of oral estradiol (30 mg vs 6 mg). The study . . . [Full Text of this Article]
Author Affiliations: Department of Medicine, Division of Hematology Oncology, University of California, San Francisco (Dr Munster); and Department of Medicine, Division of Hematology/Oncology, Department of Pathology, Department of Surgery, University of Alabama at Birmingham (Dr Carpenter).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer: A Phase 2 Randomized Study
, , , , , , , , , , , , and
JAMA. ;302():774-780.
FULL TEXT
|
